High Q Foundation

PsychoGenics expands Huntington disease research collaboration with High Q Foundation and CHDI

PsychoGenics Inc. Tarrytown, New York has expanded its research collaboration with the High Q Foundation and CHDI, Inc. to phenotype transgenic mouse models of Huntington disease (HD) and evaluate potential therapeutics in those models.  more... (pdf)

Trophos SA and CHDI, Inc. extend partnership to develop promising compounds in models relevant to Huntington disease

Trophos SA, a biopharmaceutical company sepcializing in the discovery and development of drugs for neurodegenerative diseases and CHDI, Inc. (CHDI), a non-profit organization that supports translational research aimed at finding treatments that prevent or slow the progression of Huntington disease (HD), announced today the extension of a strategic collaboration to discover and develop drugs for Huntington disease.  more... (pdf)

CHDI selects Amphora Discovery's integrated discovery services in pursuit of Huntington disease cure

Amphora Discovery announced today that CHDI, Inc., a non-profit organization pursuing a biotech approach to rapidly discover and develop drugs that prevent or slow Huntington disease (HD), has signed multiple agreements that provide access to Amphora Discovery's integrated contract discovery services.  more... (pdf)

CHDI selects Evotec as strategic drug discovery partner in the search for Huntington disease treatments

Evotec AG today announced that CHDI, Inc., a not-for-profit organisation pursuing a biotech approach to finding therapies for Huntington disease, has chosen Evotec as a strategic partner for helping them advance its drug discovery programmes.  more... (pdf)

CHDI and Edison enter collaborative agreement to develop analogs of CoQ₁₀

CHDI and Edison Pharmaceuticals, Inc. today announced the formation of a partnership to develop analogs of CoQ₁₀ selectively targeted to reach the brain and address the mitochondrial component of Huntington's disease.  more... (pdf)

Galapagos and High Q Foundation announce in principle agreement on €2.4 million alliance to discover drug targets for Huntington disease

The High Q Foundation Inc., a foundation that supports research aimed at finding diagnoses, treatments, cures and preventions of Huntington Disease, and Galapagos, a genomics-based drug discovery company, today announced that they have reached agreement in principle for a two-year target discovery alliance.  more... (pdf)

Vistagen Therapeutics secures development support for new drug candidate for Huntington's disease

VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics using embryonic stem cell technologies, announced today that the High Q Foundation, Inc. has agreed to support VistaGen's preclinical efficacy studies of AV-101 for the treatment of Huntington's disease (HD).  more... (pdf)

PsychoGenics to provide testing in the R6/2 Mouse Model for Huntington disease

PsychoGenics Inc. Tarrytown, New York has signed a license agreement enabling it to provide behavioral phenotyping and compound evaluation services using the transgenic R6/2 mouse model for Huntington Disease. Huntington Disease is a devastating and ultimately fatal neurological condition for which no treatment currently exists. The Huntington animal model provides a valuable discovery tool to aid in the development of much needed drugs.  more... (pdf)

David Howland and Jamshid Arjomand join High Q research team

The High Q Foundation announced today that David Howland, Ph.D. and Jamshid Arjomand, Ph.D. have joined MRSSI, Inc. as Directors of Basic Research. Their role will be to help manage High Q’s extensive research portfolio in the field of Huntington disease (HD). They will be working closely with Drs. Allan Tobin and Ethan Signer, both Managing Directors of MRSSI and Senior Scientific Advisors to High Q, as well as with Dr. Robert Pacifici, CSO Drug Discovery & Development and Chief Scientific Advisor to CHDI, Inc. more... (pdf)

Metabolon collaborates on biomarker study for Huntington's disease

Research Triangle Park, NC, USA, January 19 2005 - Metabolon, Inc., a leader in the application of metabolomics to design novel therapies, today announced its collaboration with the High Q Foundation on a new biomarker study for Huntington's disease (HD.) more... (pdf)

Proteome Systems and High Q expand program for Huntington's disease biomarkers

Sydney, Australia and New York, USA, 15 November 2004 - Proteome Systems (ASX: PXL) and the High Q Foundation today announced the expansion of a biomarker discovery program for Huntington's disease (HD). The program is seeking to discover biomarkers that will be used for monitoring the onset and progression of HD and provide insights into the efficacy of existing and future treatments. more... (pdf)

Robert E. Pacifici to lead CHDI, Inc.'s HD drug discovery effort

The High Q Foundation announced today that Robert E. Pacifici, Ph.D. will head up CHDI, Inc., the Foundation's drug discovery and development entity. Dr Pacifici joins MRSSI as CSO-Drug Discovery & Development and Chief Scientific Advisor to CHDI, Inc. He will lead the translational research effort to identify therapeutic compounds for Huntington's disease (HD). CHDI, Inc. was established in 2003 as a not-for-profit entity pursuing a biotech approach to finding therapies for HD. more... (pdf)

Proteome Systems and High Q collaborate to identify and characterize biomarkers for monitoring disease progression and treatment of Huntington's disease

Sydney, Australia and New York, USA, 19 April 2004 - Proteome Systems and the High Q Foundation today announced an agreement to collaborate on a proteomic program for Huntington’s Disease (HD), comprising biomarker identification and molecular characterization of the Huntingtin protein. Proteome Systems will characterize changes in protein expression and modification that result from malfunction of the Huntingtin protein in order to identify biomarkers of HD. Candidate biomarkers will be formulated into tests using Proteome Systems DiagnostIQ platform and used for monitoring disease progression and measuring outcomes of clinical trials. Proteome Systems will also apply its proprietary advanced technologies for characterization of large proteins and protein modification analysis to identify differences between the wild-type and mutant Huntingtin proteins. more... (pdf)

HSG, HDSA, HSC, HDF, IHA, WFN, WCHD and NINDS announce the Huntington Project

“Now is the time to find treatments that make a difference in the lives of people with Huntington’s disease!”

The Huntington Study Group (HSG), Huntington’s Disease Society of America (HDSA), Huntington Society of Canada (HSC), Hereditary Disease Foundation (HDF), International Huntington Association (IHA), World Federation of Neurology Research Group on HD (WFN), World Congress on HD 2005 (WCHD), and National Institute of Neurological Disorders and Stroke (NINDS) announce an ambitious new initiative called the Huntington Project. The Huntington Project brings together under one expansive umbrella the clinical research efforts for Huntington’s disease (HD) that are underway throughout the world. The entire HD community, regardless of geographical location, will be able to take part in the Huntington Project. more... (pdf)

Nominations Sought for Compounds to Test for Huntington's Disease

The Huntington Project has launched a broad-based effort to systematically evaluate compounds to test as potential treatments for Huntington’s disease. As a first step in this effort, the Huntington Project is asking everyone in the HD community – clinicians, scientists, individuals affected by HD, and advocacy organizations -- to nominate experimental treatments that they believe should be considered for research evaluation. Nominations can be made via the Huntington Project website (www.huntingtonproject.org) by clicking on the SET-HD tab. SET-HD stands for Systematic Evaluation of Treatments for HD. more... (pdf)

Allan J. Tobin joins High Q Foundation scientific team

The High Q Foundation announced today that Allan J. Tobin will join Ethan Signer as a Manager Director of MRSSI and Senior Scientific Advisor to the Foundation. Tobin and Signer will spearhead the Foundation's scientific programs aimed at finding interventions for Huntington's disease (HD). more... (pdf)